GSK agreed to acquire Nuvalent for $10.6 billion, adding near-commercial and clinical-stage targeted programs for NSCLC. The deal brings zidesamtinib (NVL-520) and eladalkib (NVL-655), both designed to address resistance in ROS1- and ALK-driven disease and positioned for potential launches later this year if FDA reviews finish on schedule. Nuvalent’s pipeline also includes NVL-330, a HER2 inhibitor in early development. The acquisition is structured to strengthen GSK’s oncology growth engine with assets carrying Breakthrough Therapy and Orphan Drug designations, including planned FDA decision dates later in 2026. For investors and competitors, the transaction signals continued appetite for precision oncology programs where target selectivity and brain penetration are central to differentiation.